President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.
The Human Drugs Program at the US Food and Drug Administration was largely left out of the proposed increases in the fiscal year 2021 budget in what appears to be an adjustment of agency-wide priorities.
The budget request put more focus on other areas, only offering an increase for compounding and vaccine activities within the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
